Emerging antibody–drug conjugates in lung cancer: highlights from the 2026 ASCO Annual Meeting
- 1Department of Oncology, Provincial Hospital Affiliated to Shandong First Medical University
- 2Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University
Abstract
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting presented substantial new data on antibody–drug conjugates (ADCs) in lung cancer, highlighting the ongoing expansion of ADC-based strategies from later-line treatment toward first-line combination regimens. This focused narrative review summarizes and discusses the efficacy and safety findings of ADCs targeting TROP2, HER2, Nectin-4, PD-L1, c-Met, B7-H3, DLL3, SEZ6, and other emerging targets in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with particular attention to emerging ADC plus immune checkpoint inhibitor combinations in the first-line setting. Taken together, these findings highlight an expanding ADC landscape in lung cancer. However, many of the emerging strategies remain supported primarily by preliminary conference-reported or early-phase data and therefore require confirmation in mature peer-reviewed studies and adequately powered randomized clinical trials.
Related
- Efficacy and safety of antibody-drug conjugates in advanced small cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
- Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials
- Combination of antibody–drug conjugates with immunotherapy: a new paradigm in cancer treatment
- A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
- Antibody‒cell conjugates: A novel "off-the-shelf" modality bridging ADCs and CAR-T for cancer immunotherapy.
BibTeX
@article{wang2026emerging,
title = {{Emerging antibody–drug conjugates in lung cancer: highlights from the 2026 ASCO Annual Meeting}},
author = {Xiaolei Wang and Jiayuan Miao and Yuxuan Bao and Wanli Wang and Xin Yan and Mei Wang and Hongchang Shen},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1943176},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1943176/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Emerging antibody–drug conjugates in lung cancer: highlights from the 2026 ASCO Annual Meeting
AU - Xiaolei Wang
AU - Jiayuan Miao
AU - Yuxuan Bao
AU - Wanli Wang
AU - Xin Yan
AU - Mei Wang
AU - Hongchang Shen
PY - 2026
DA - 2026/10/06
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1943176
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1943176/full
AB - The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting presented substantial new data on antibody–drug conjugates (ADCs) in lung cancer, highlighting the ongoing expansion of ADC-based strategies from later-line treatment toward first-line combination regimens. This focused narrative review summarizes and discusses the efficacy and safety findings of ADCs targeting TROP2, HER2, Nectin-4, PD-L1, c-Met, B7-H3, DLL3, SEZ6, and other emerging targets in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with particular attention to emerging ADC plus immune checkpoint inhibitor combinations in the first-line setting. Taken together, these findings highlight an expanding ADC landscape in lung cancer. However, many of the emerging strategies remain supported primarily by preliminary conference-reported or early-phase data and therefore require confirmation in mature peer-reviewed studies and adequately powered randomized clinical trials.
SN - 2234-943X
ER -